AngioDynamics, Inc. (ANGO) Shares Sold by First Quadrant L P CA
First Quadrant L P CA lowered its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 51.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,159 shares of the medical instruments supplier’s stock after selling 57,304 shares during the quarter. First Quadrant L P CA owned approximately 0.15% of AngioDynamics worth $943,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of AngioDynamics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,128,777 shares of the medical instruments supplier’s stock valued at $54,285,000 after purchasing an additional 14,823 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of AngioDynamics by 14.4% during the second quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock worth $31,416,000 after buying an additional 243,825 shares during the period. Broadfin Capital LLC boosted its position in shares of AngioDynamics by 14.9% during the second quarter. Broadfin Capital LLC now owns 1,683,252 shares of the medical instruments supplier’s stock worth $27,286,000 after buying an additional 217,800 shares during the period. Northern Trust Corp boosted its position in shares of AngioDynamics by 14.9% during the second quarter. Northern Trust Corp now owns 1,202,941 shares of the medical instruments supplier’s stock worth $19,500,000 after buying an additional 155,951 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of AngioDynamics by 86.3% during the second quarter. Wells Fargo & Company MN now owns 1,015,594 shares of the medical instruments supplier’s stock worth $16,463,000 after buying an additional 470,522 shares during the period. 95.67% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “AngioDynamics, Inc. (ANGO) Shares Sold by First Quadrant L P CA” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/11/04/angiodynamics-inc-ango-shares-sold-by-first-quadrant-l-p-ca.html.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) opened at $17.23 on Friday. The company has a market cap of $623.43 million, a PE ratio of 24.61, a price-to-earnings-growth ratio of 1.74 and a beta of 1.05. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.48 and a current ratio of 2.34.
AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). The business had revenue of $85.40 million for the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. AngioDynamics’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.17 EPS. analysts anticipate that AngioDynamics, Inc. will post 0.65 EPS for the current year.
Several brokerages have recently issued reports on ANGO. Zacks Investment Research upgraded AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Tuesday, October 3rd. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a report on Sunday, October 8th. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a report on Friday, August 25th. Finally, Barclays PLC lowered their price target on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $18.60.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.